This site and its domain are for sale. Email the owner if you want to talk about it.

compoundglp.com

How to Judge a Compounding Pharmacy's Quality

Nobody publishes a ranking of compounders, so the useful question is whose records can be checked, and the sticker and the binder agree.

A closed three-ring binder and a blank adhesive label sit on a steel desk beside an empty glass vial in a clean room.

The most respected credential a compounding pharmacy can earn is one it is not required to have. The Pharmacy Compounding Accreditation Board, or PCAB, runs a voluntary accreditation program, which a consumer explainer titled “Is your compounded semaglutide and tirzepatide safe?” describes as “an extra optional step that some compounding pharmacies take to be legitimized by a third party.” A pharmacy that skips it is still a pharmacy. There is no federal ranking, no league table and no official list of the good ones.

So if you typed best compounding pharmacy into a search box, the plain answer is that nobody publishes that list, and the facts available here cannot produce one. What exists instead is a short set of things that can be checked: whether the pharmacy is accredited (by PCAB, mostly), whether it follows USP 797, the sterile-compounding chapter, how it tests what it makes, and where its active ingredient comes from. Those four things are roughly what “quality” means in this business. There is a simple way to evaluate them and a sophisticated way, and they end up in the same place.

Why nobody ranks the best compounding pharmacy

The market is big and the referees are scattered. At the peak in 2024, nearly one in three Americans taking a GLP-1 drug reported getting it from a compounding pharmacy, and the whole U.S. compounding market was valued at about $6.98 billion in 2025, with projections of $12.79 billion by 2035. That is a lot of vials.

Meanwhile, 503A pharmacies (the traditional, patient-specific kind) are regulated mainly by state boards of pharmacy rather than the FDA, and they are not required to register with the FDA or follow the Current Good Manufacturing Practices that drug manufacturers must meet. So the referee is fifty different referees. Each one is grading a different game.

Everyone here is acting sensibly from where they sit. A state board inspects the pharmacies it licenses, the FDA focuses on what federal law hands it, and a pharmacy invests in whatever credential the people paying it actually ask about. Nobody’s job description includes “publish a ranking.”

The simple version: look for the sticker

The simple way to judge a compounder is to ask whether it has PCAB accreditation. If yes, good. If no, less good. It’s fine.

And the sticker does mean something: an outside party came and looked. The accreditation is optional, so having it tells you the pharmacy chose to be looked at. Well, mostly chose. Washington and Ohio now require verifiable PCAB accreditation for nonresident compounding pharmacy licensure, so the stricter thing to say is that PCAB is optional the way a passport is optional. Nobody needs one to stay home, but a pharmacy that wants to ship into Washington or Ohio from another state has to have it. Some of the most voluntary-looking stickers in the industry are really travel documents.

That is the dumb version. Its weakness is that it outsources the judgment to someone else. Its strength is the same.

The sophisticated version: read the rulebook

The sophisticated way is to skip the sticker and ask what rules the pharmacy actually lives under. A 503A pharmacy must comply with USP 795 (nonsterile compounding) and USP 797 (sterile compounding), plus its state board’s regulations. It is exempt from the federal cGMP framework in 21 CFR Parts 210 and 211 when it compounds for a patient-specific prescription. A 503B outsourcing facility, on the other hand, must validate every process under cGMP.

Here is a concrete difference. Every compounded drug gets a beyond-use date, which is basically the pharmacy’s version of an expiration date. A 503A pharmacy may rely on default date categories set out in USP 797. The FDA’s draft cGMP guidance for outsourcing facilities expects those dates to be backed by stability data for the specific formulation. One tier uses the standard chart, and the other has to prove its own numbers.

The stricter tier is not spotless either. A review of FDA Form 483 data (the list of problems inspectors write down on site) presented at the FDA Compounding Quality Center of Excellence’s 2024 conference found production and process control deficiencies in close to 29 percent of all observations issued to outsourcing facilities. Nearly three in ten. Under the strict rules.

Then there is the paperwork. On September 18, 2026, the FDA sent a warning letter to a Houston compounding pharmacy citing pretextual significant-difference determinations, boilerplate prescribing records, and sterile compounding failures including “inadequate smoke studies and rewritten media fill records.” A smoke study shows how air moves around the sterile work area. A media fill is a rehearsal of the compounding process using a growth medium, to see whether anything grows. The point of both is a record that shows the room works. (The point is not a record that shows the room works after some editing.) I mean, one imagines the inspection going something like this, in invented dialogue: “Hey, can we see the media fill records?” “Sure. Which draft?” It must be tiring to keep improving documents that were presumably fine the first time.

Where the active ingredient comes from

Federal law gives a 503A pharmacy exactly three ways to use a bulk drug substance: it meets an applicable USP or National Formulary monograph, it is a component of an FDA-approved drug, or it appears on a list the FDA developed. Semaglutide has no monograph. The sodium and acetate salt forms fail all three tests: no monograph, not part of any approved drug, not on the list. On April 27, 2023, the FDA told the National Association of Boards of Pharmacy it was not aware of any basis for compounding with those salts that would satisfy federal requirements. The Mississippi Board of Pharmacy put it in writing to its licensees, warning that salt compounding “may draw action from FDA or the board itself.” (The site’s piece on salt forms covers the chemistry.) Presumably every pharmacy that used the salts did so for their fine chemical properties, and not because they were the semaglutide on offer that week.

For ingredients that do qualify, the rule is that a 503A pharmacy compounding from a bulk substance must buy from a registered manufacturer and get a valid certificate of analysis. The certificate is a document from the supplier saying what is in the drum. This works a lot like the itemized receipt a restaurant staples to a delivery bag. It is useful and specific, and it was printed by the restaurant.

Which is why the origin question gets asked. A Brookings Institution report, cited by Novo Nordisk (which sells brand semaglutide and sues compounders, so it has a view), said many compounded semaglutide products rely on API imported from facilities in China that lack FDA oversight or quality controls. How many, exactly, is not settled by the facts here; the percentage Novo quotes is described in its own source as incomplete.

What testing does and does not tell you

The facts here do not settle how often a 503A pharmacy must test its finished product, or by whose lab. What they do show is a ladder: supplier certificates at the bottom, default dating under USP 797 for 503A pharmacies, and formulation-specific stability data expected of outsourcing facilities. Each rung is more evidence produced by the party being judged, or by its vendor.

And quality does not stop at the vial. In a 2023 poison-control case series on compounded semaglutide errors, one patient reported receiving a vial and syringes for self-administration with no pharmacist counseling on how to use them. That is a weird gap for a sterile process to have at the very end. (The site’s piece on dosing errors has the rest.)

Now a made-up scenario, purely illustrative. Suppose a patient decides to run the sophisticated version personally. She requests the certificate of analysis, then the supplier’s registration, then flies to the API plant to watch a batch, then buys a fog machine to run her own smoke study on the pharmacy’s hood, then asks to rehearse a media fill herself, then sits in the clean room for a fourteen-day incubation reading Yelp reviews of other clean rooms. She has now audited one vial. Lol.

How the two versions end up in the same place

Look, the simple version says: trust the sticker. The sophisticated version says: trust the records. But the sticker is just someone else having read the records, and the records are written by the pharmacy, about the pharmacy. The long road and the short road both end at the same desk, reading the same binder.

Anyway, the regulators have noticed that the binder sometimes comes from far away. FDA warning letters to telehealth companies name the platform itself, not just the compounding pharmacy, as responsible for misbranding the drug. So even the question of whose pharmacy it is has gotten complicated.

The best compounding pharmacy is the one whose records are true.

Sources

  1. Is your compounded semaglutide and tirzepatide safe?
  2. Quality Control In Compounding Pharmacy: 2026 Checklist
  3. Compounded Semaglutide vs Brand Name Comparison: What's Actually in Your Injection?
  4. 503A vs. 503B: A Quick-Guide to Compounding Pharmacy Designations & Regulations
  5. cGMP Expectations for Outsourcing Facilities
  6. Semaglutide Salt Forms: Why the Base Matters
  7. FDA clarifies position on compounding semaglutide sodium
  8. Compounded GLP-1 Marketing After the Shortage Ended
  9. Compounded GLP-1s: Why doctors worry and the FDA is cracking down
  10. Semaglutide Sodium vs Base: What FDA Says and What to Ask
  11. Novo Nordisk expands legal action to protect US patients from unsafe, non-FDA-approved compounded "semaglutide"
  12. FDA Warning Letters to Telehealth Companies Selling Compounded Drugs
  13. Administration errors of compounded semaglutide reported to a poison control center-Case series

Compound GLP explains the law and published research. It is not medical or legal advice, and it never recommends a dose, a pharmacy or a product. Talk to a clinician before you start, stop or change any medicine.

Read next